Home›Research›Compare›Cagrilintide vs CJC-1295 (without DAC)
Peptide ComparisonCagrilintide vs CJC-1295 (without DAC)
Cagrilintide
AM833
Half-life: ~7 days
21 providers listed
CJC-1295 (without DAC)
CJC 1295
Half-life: ~30 minutes
454 providers listed
Cagrilintide and CJC-1295 (without DAC) target different goals — Cagrilintide for Metabolic, CJC-1295 (without DAC) for GH and IGF-1 elevation. They're compared here for reference, not as direct substitutes.
Cagrilintide
Half-life
~7 days
CJC-1295 (without DAC)
Half-life
~30 minutes
Cagrilintide and CJC-1295 (without DAC) target different goals — Cagrilintide for Metabolic, CJC-1295 (without DAC) for GH / IGF Axis. They're compared here for reference; there isn't a single “better” choice between them.
Cagrilintide
CJC-1295 (without DAC)
Cagrilintide
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with o…
Combination of cagrilintide and semaglutide 2·4 mg for weight management in adults with overweight and obesit…
Cagrilintide 2·4 mg once-weekly subcutaneous injection in adults with overweight or obesity (SCALE-CAGRI): a…
+5 more
CJC-1295 (without DAC)
Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)…
Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune syst…
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Imp…
About Cagrilintide
Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination
About CJC-1295 (without DAC)
CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analog that binds and activates pituitary GHRH receptors to stimulate brief, pulsatile growth hormone release. Lacking the Drug Affinity Complex, it is not albumin-bound and clears within roughly half an hour, producing discrete GH pulses rather than the sustained elevation of the DAC form.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Cagrilintide
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Given mechanistic overlap with GLP-1 agonists when used as CagriSema, monitor thyroid C-cell markers (calcitonin), lipase for pancreatitis risk, and a baseline metabolic panel. Amylin-specific monitoring guidance is evolving as Phase 3 data matures; follow prescribing protocol of the co-administered agent.
CJC-1295 (without DAC)
Class-based (investigational)
Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.
global — WADA
This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.
sourceCJC-1295 (without DAC)
Ipamorelin
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.
Cagrilintide
CJC-1295 (without DAC)
Where to source these peptides
Cagrilintide
21 listed
Browse directory →
Providers offeringCJC-1295 (without DAC)
454 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
Related Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Cagrilintide vs CJC-1295 (without DAC) — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/cagrilintide/cjc-1295